CD47 Monoclonal Antibodies


CD47 mAbs developed in Anogen:


CD47 is a ubiquitously expressed 50 kDa transmembrane protein with an extracellular N-terminal IgV domain. CD47 inhibits phagocytosis through interaction with signal regulatory protein a (SIRPa) on macrophages and other phagocytic cells. Normal cells, especially cells in brain tissue, placenta, prostate, bladder and fallopian tube, expressed abundant CD47. Aged erythrocytes and spontaneous apoptotic cells express less CD47 and are more likely been phagocytized. CD47 expression levels in many cancer cells are elevated. It is believed that CD47 is a "self" marker that helps cancer cells to escape from immunity. Anogen has developed 20 clones of CD47 monoclonal antibodies (mAbs) recently. The inhibition of CD47-SIPRa binding by these antibodies has been evaluated in our lab. Among these mAbs, several clones (8H7, 9F10, 6A7) have demonstrated outstanding inhibitory effect. These clones have great potential for therapeutic applications after humanization.


The new research progress in CD47: CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma: https://www.nejm.org/doi/full/10.1056/NEJMoa1807315